title: Oncolysis by paramyxoviruses: preclinical and clinical studies.
abstract: Preclinical studies demonstrate that a broad spectrum of human malignant cells can be killed by oncolytic paramyxoviruses, which include cells of ecto-, endo-, and mesodermal origin. In clinical trials, significant reduction in size or even complete elimination of primary tumors and established metastases are reported. Different routes of viral administration (intratumoral, intravenous, intradermal, intraperitoneal, or intrapleural), and single- versus multiple-dose administration schemes have been explored. The reported side effects are grade 1 and 2, with the most common among them being mild fever. Some advantages in using para-myxoviruses as oncolytic agents versus representatives of other viral families exist. The cytoplasmic replication results in a lack of host genome integration and recombination, which makes paramyxoviruses safer and more attractive candidates for widely used therapeutic oncolysis in comparison with retroviruses or some DNA viruses. The list of oncolytic paramyxovirus representatives includes attenuated measles virus (MV), mumps virus (MuV), low pathogenic Newcastle disease (NDV), and Sendai (SeV) viruses. Metastatic cancer cells frequently overexpress on their surface some molecules that can serve as receptors for MV, MuV, NDV, and SeV. This promotes specific viral attachment to the malignant cell, which is frequently followed by specific viral replication. The paramyxoviruses are capable of inducing efficient syncytium-mediated lyses of cancer cells and elicit strong immunomodulatory effects that dramatically enforce anticancer immune surveillance. In general, preclinical studies and phase 1-3 clinical trials yield very encouraging results and warrant continued research of oncolytic paramyxoviruses as a particularly valuable addition to the existing panel of cancer-fighting approaches.
authors.affiliation: Biopolymer Design LLC, Acton, Massachusetts, USA ; Engelhardt Institute of Molecular Biology, Moscow, Russia.
authors.forename: Olga V
authors.initials: OV
authors.lastname: Matveeva
authors.affiliation: Division of Surgical Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA.
authors.forename: Zong S
authors.initials: ZS
authors.lastname: Guo
authors.affiliation: Blokhin Russian Cancer Research Center, Moscow, Russia.
authors.forename: Vyacheslav M
authors.initials: VM
authors.lastname: Senin
authors.affiliation: Huntsman Cancer Institute Salt Lake City, Utah, USA.
authors.forename: Anna V
authors.initials: AV
authors.lastname: Senina
authors.affiliation: National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, Maryland, USA.
authors.forename: Svetlana A
authors.initials: SA
authors.lastname: Shabalina
authors.affiliation: Engelhardt Institute of Molecular Biology, Moscow, Russia.
authors.forename: Peter M
authors.initials: PM
authors.lastname: Chumakov